Life science leader executive editor blog Life science leader executive editor blog

Startups & Outsourcing — Opposite Poles or Virtual Partners?
Startups & Outsourcing — Opposite Poles or Virtual Partners? Let’s face it, finding the money often captures all but a few crumbs of the typical startup CEO’s attention. Laser-sharp illustrations in the company’s dog-and-pony show may present its scientific platform with convincing clarity and purpose, but traditionally, investment conferences have not been a place where the dollar-hungry startup talks about the infrastructure it must build or hire to turn its science into a medical...  Continue Reading...
Reliving the Past, Shaping the Future of Cancer Therapy
Reliving the Past, Shaping the Future of Cancer Therapy What prompted this reverie was a news item on AZ’s new “crowdsourcing” approach to cancer-drug treatment. The report uncritically hailed the program as a veritable revolution...  Continue Reading...
Was It the Weather? — Why Biotech Came from California
Was It the Weather? — Why Biotech Came from California Could climate have played as big a role as science and capital in the origins of the biotechnology industry? The question is about beginning: did this brand new industry need that extra push of a beneficent clime to overcome the unlikelihood of such a business ever being born?  Continue Reading...
BIO 2015 — A Big Tent Can Be Hard on the Feet
BIO 2015 — A Big Tent Can Be Hard on the Feet What is biotechnology? A manufacturing machine? A business model? An industry built on manipulating life itself for medical and other purposes? Wait. What?  Continue Reading...
Back In Action — At and After ASCO 2015
Back In Action — At and After ASCO 2015 At ASCO (American Society of Clinical Oncology) most of the experts are leading researchers in the immunotherapy field with whom I spoke at last year’s ASCO meeting. This time, I essentially collected their views on how cancer immunotherapy has progressed during the past year.  Continue Reading...
Love Me, Love Me Not — The Life Science Industry’s Paradox
Love Me, Love Me Not — The Life Science Industry’s Paradox Cold-hearted logic dominates the quest for shareholder value, even as industry insiders complain that “nobody loves us.” What better example of the conundrum exists than the current commentary about Gilead and its wonder drugs for Hep C?  Continue Reading...
HBA Honors Women Leading the Industry — The West Coast Simulcast
HBA Honors Women Leading the Industry — The West Coast Simulcast After some pleasant conversation at Genentech, I did not realize several of the women at the adjacent table were to be members of one of the best discussion panels I’ve ever witnessed at the HBA Woman of the Year award ceremony.  Continue Reading...
Durable Take-Homes from DCAT Week 15 — And Our Annual CMO Awards Celebration
Durable Take-Homes from DCAT Week 15 — And Our Annual CMO Awards Celebration It is now weeks since I returned home from this year’s DCAT Week conference in New York City, and the delay has benefitted my perspective, testing each “take-home” for durability of importance over time. The important links remain, while the non-essential ones slough off like falling leaves.  Continue Reading...
Valor For Invention
Valor For Invention A lot of discussion at Biocom’s Global Partnering Conference about large companies’ continuing inability to deal with risk. I’m not reflecting public perception here, but the opinions of people in the industry, in companies large and small.  Continue Reading...
Pharma — Frozen in Place or Running from the Past?
Pharma — Frozen in Place or Running from the Past? We editors have debates about whether Pfizer is pharma or “biopharma.” After all, what self-respecting Big Pharma would risk being caught dead these days with no biotech-based products? Does that mean they have all outgrown the pharma label?  Continue Reading...

BE A CONTRIBUTOR